ANIP Insider Trading
Insider Ownership Percentage: 12.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $13,402,529.50
ANI Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at ANI Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
ANI Pharmaceuticals Share Price & Price History
Current Price: $69.21
Price Change: ▲ Price Increase of +0.01 (0.01%)
As of 04/17/2025 05:00 PM ET
ANI Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for ANI Pharmaceuticals (NASDAQ:ANIP)
76.05% of ANI Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at ANIP by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
ANI Pharmaceuticals Institutional Trading History
Data available starting January 2016
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Read More on ANI Pharmaceuticals
Today's Range
Now: $69.21
52 Week Range
Now: $69.21
Volume
299,660 shs
Average Volume
271,449 shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
Who are the company insiders with the largest holdings of ANI Pharmaceuticals?
ANI Pharmaceuticals' top insider shareholders include:
- Meridian Venture Partners Ii L (Major Shareholder)
- Muthusamy Shanmugam (COO)
- Nikhil Lalwani (CEO)
- Chad Gassert (SVP)
- Stephen P Carey (CFO)
- James G Marken (SVP)
- Meredith Cook (VP)
- Christopher Mutz (Insider)
- Ori Gutwerg (SVP)
- Krista Davis (SVP)
- Antonio R Pera (Director)
- Renee P Tannenbaum (Director)
Learn More about top insider investors at ANI Pharmaceuticals.
Who are the major institutional investors of ANI Pharmaceuticals?
Which major investors are selling ANI Pharmaceuticals stock?
Within the previous quarter, ANIP stock was sold by these institutional investors:
- Assenagon Asset Management S.A.
- Wedge Capital Management L L P NC
- Kings Path Partners LLC
- Summit Global Investments
- BTC Capital Management Inc.
- Rhumbline Advisers
Within the previous year, company insiders that have sold ANI Pharmaceuticals company stock include:
- Meridian Venture Partners Ii L (Major Shareholder)
- Muthusamy Shanmugam (COO)
- Nikhil Lalwani (CEO)
- Chad Gassert (SVP)
- Stephen P Carey (CFO)
- James G Marken (SVP)
- Meredith Cook (VP)
- Christopher Mutz (Insider)
- Ori Gutwerg (SVP)
Learn More investors selling ANI Pharmaceuticals stock.
Which major investors are buying ANI Pharmaceuticals stock?
Within the last quarter, ANIP stock was purchased by institutional investors including:
- GAMMA Investing LLC
- Sowell Financial Services LLC
- GAMMA Investing LLC